Teva Pharmaceutical Industries
Market Cap
US$10.7b
Last Updated
2019/12/10 23:44 UTC
Data Sources
Company Financials +
Executive Summary
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Fair value with moderate growth potential.
Similar Companies
Share Price & News
How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TEVA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-7.5%
TEVA
2.2%
US Pharmaceuticals
1.1%
US Market
1 Year Return
-48.7%
TEVA
0.5%
US Pharmaceuticals
17.8%
US Market
Return vs Industry: TEVA underperformed the US Pharmaceuticals industry which returned 0.5% over the past year.
Return vs Market: TEVA underperformed the US Market which returned 17.8% over the past year.
Shareholder returns
| TEVA | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.5% | 2.2% | 1.1% |
| 30 Day | 2.0% | 4.8% | 1.4% |
| 90 Day | 14.1% | 6.5% | 3.9% |
| 1 Year | -48.7%-48.7% | 3.0%0.5% | 20.3%17.8% |
| 3 Year | -74.1%-74.8% | 29.7%20.4% | 44.8%35.4% |
| 5 Year | -81.5%-82.8% | 27.7%14.3% | 71.3%52.4% |
Price Volatility Vs. Market
How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
Teva Pharmaceutical Industries Limited Just Released Its Third-Quarter Earnings: Here's What Analysts Think1 month ago | Simply Wall St
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load2 months ago | Simply Wall St
How Much Of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Do Institutions Own?Valuation
Is Teva Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TEVA ($9.49) is trading below our estimate of fair value ($25.08)
Significantly Below Fair Value: TEVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TEVA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: TEVA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TEVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TEVA is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Teva Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
105.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: TEVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TEVA's is expected to become profitable in the next 3 years.
Revenue vs Market: TEVA's revenue (0.4% per year) is forecast to grow slower than the US market (7.4% per year).
High Growth Revenue: TEVA's revenue (0.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEVA's Return on Equity is forecast to be low in 3 years time (15.5%).
Next Steps
Past Performance
How has Teva Pharmaceutical Industries performed over the past 5 years?
-54.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TEVA is currently unprofitable.
Growing Profit Margin: TEVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TEVA is unprofitable, and losses have increased over the past 5 years at a rate of -54.8% per year.
Accelerating Growth: Unable to compare TEVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TEVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).
Return on Equity
High ROE: TEVA has a negative Return on Equity (-28.93%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Teva Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: TEVA's short term assets ($12.5B) do not cover its short term liabilities ($14.1B).
Long Term Liabilities: TEVA's short term assets ($12.5B) do not cover its long term liabilities ($28.2B).
Debt to Equity History and Analysis
Debt Level: TEVA's debt to equity ratio (180.5%) is considered high.
Reducing Debt: TEVA's debt to equity ratio has increased from 45% to 180.5% over the past 5 years.
Balance Sheet
Inventory Level: TEVA has a low level of unsold assets or inventory.
Debt Coverage by Assets: TEVA's debt is not covered by short term assets (assets are 0.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TEVA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TEVA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: TEVA is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TEVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Teva Pharmaceutical Industries's salary, the management and board of directors tenure and is there insider trading?
2.5yrs
Average management tenure
CEO
Kåre Schultz (58yo)
2.1yrs
Tenure
US$32,469,875
Compensation
Mr. Kåre Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry ...
CEO Compensation Analysis
Compensation vs Market: Kåre's total compensation ($USD32.47M) is above average for companies of similar size in the US market ($USD10.90M).
Compensation vs Earnings: Kåre's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: TEVA's management team is considered experienced (2.5 years average tenure).
Board Age and Tenure
2.6yrs
Average Tenure
63yo
Average Age
Experienced Board: TEVA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.7%.
Management Team
Kåre Schultz (58yo)
President
- Tenure: 2.1yrs
- Compensation: US$32.47m
Eric Drapé (57yo)
Executive Vice President of Global Operations
- Tenure: 0.2yrs
Kevin Mannix
Senior Vice President of Investor Relations
- Tenure: 0yrs
Sven Dethlefs (50yo)
Executive Vice President of Global Marketing & Portfolio
- Tenure: 2.1yrs
Hafrun Fridriksdottir (57yo)
Executive Vice President of Global R&D
- Tenure: 2.8yrs
- Compensation: US$5.98m
Mark Sabag (48yo)
Executive VP
- Tenure: 0.9yrs
- Compensation: US$5.25m
Nir Baron
Senior VP & Chief Internal Auditor
- Tenure: 5.6yrs
David Stark (50yo)
Executive VP & Chief Legal Officer
- Tenure: 3.1yrs
Deborah Griffin
Senior VP & Chief Accounting Officer
- Tenure: 0yrs
Lori Queisser
Senior VP & Global Compliance Officer
- Tenure: 4.5yrs
Board Members
Chemi Peres (60yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$235.53k
Murray Goldberg (74yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$245.71k
Sol Barer (72yo)
Independent Chairman of the Board
- Tenure: 2.8yrs
- Compensation: US$378.00k
Amir Elstein (63yo)
Independent Director
- Tenure: 10.9yrs
- Compensation: US$246.32k
Kåre Schultz (58yo)
President
- Tenure: 2.1yrs
- Compensation: US$32.47m
Jerry Lieberman (72yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$250.72k
Roberto Mignone (47yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$241.43k
Jean-Michel Halfon (67yo)
Independent Director
- Tenure: 5.5yrs
- Compensation: US$232.68k
Rose Crane (59yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$235.00k
Perry Nisen (63yo)
Independent Director
- Tenure: 2.4yrs
- Compensation: US$211.71k
Company Information
Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Teva Pharmaceutical Industries Limited
- Ticker: TEVA
- Exchange: NYSE
- Founded: 1901
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.724b
- Shares outstanding: 1.09b
- Website: https://www.tevapharm.com
Number of Employees
Location
- Teva Pharmaceutical Industries Limited
- 5 Basel Street
- Petach Tikva
- 4951033
- Israel
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TEVA | NYSE (New York Stock Exchange) | Yes | ADR(CNV 1 ORD ILS0.10) | US | USD | Feb 1982 |
| TEV | DB (Deutsche Boerse AG) | Yes | ADR(CNV 1 ORD ILS0.10) | DE | EUR | Feb 1982 |
| TEVA N | BMV (Bolsa Mexicana de Valores) | Yes | ADR(CNV 1 ORD ILS0.10) | MX | MXN | Feb 1982 |
| TEVA | SWX (SIX Swiss Exchange) | Yes | ADR(CNV 1 ORD ILS0.10) | CH | CHF | Feb 1982 |
| 0LER | LSE (London Stock Exchange) | Yes | ADR(CNV 1 ORD ILS0.10) | GB | USD | Feb 1982 |
| TEVA | WBAG (Wiener Boerse AG) | Yes | ADR(CNV 1 ORD ILS0.10) | AT | EUR | Feb 1982 |
| TEVJ.F | OTCPK (Pink Sheets LLC) | Ordinary Shares | US | USD | Jun 1994 | |
| TEVA | TASE (The Tel-Aviv Stock Exchange) | Ordinary Shares | IL | ILS | Jun 1994 |
Biography
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through tw ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/10 23:44 |
| End of Day Share Price | 2019/12/10 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.